Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 7/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471574 | 0.91 | BACE1 (0.53) | RXRANR1H2NR1H3LTA4HNR3C2 | |
| SCHEMBL3472909 | 0.91 | NPC1 (0.50) | RXRANR1H2NR1H3LTA4HNR3C2 | |
| SCHEMBL3472674 | 0.84 | RXRA (0.49) | RXRANR1H2NR1H3NR3C2PTGS2 | |
| SCHEMBL3471877 | 0.81 | RXRA (0.50) | RXRANR1H2NR1H3LTA4HNR3C2 | |
| SCHEMBL3477579 | 0.81 | RXRA (0.55) | RXRANR1H2NR1H3ESR1ESR2 | |
| SCHEMBL3473808 | 0.80 | RXRA (0.55) | RXRANR1H2NR1H3NR3C2PTGS2 | |
| SCHEMBL1870716 | 0.79 | HRH3 (0.57) | PTGS2HRH3HRH1KCNH2 | |
| SCHEMBL3471829 | 0.79 | CHRNB2 (0.52) | RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL3474534 | 0.79 | RXRA (0.50) | RXRANR1H2NR1H3NR3C2PTGS2 | |
| SCHEMBL1874492 | 0.78 | PTGS1 (0.57) | LTA4HPTGS2HRH3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.